Strategy reduced nephropathy risky by 21% in patients with type 2 diabetes, study finds. Intensive glucose control with gliclazide (modified release) and other agents reduced the risk of nephropathy ...
We randomly assigned 11,140 patients with type 2 diabetes to undergo either standard glucose control or intensive glucose control, defined as the use of gliclazide (modified release) plus other drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results